| Leading the digital transformation of clinical trials… Achievements in securing global competitiveness recognized
JNPMEDI (CEO Jung Kwon-ho) has received a commendation from the Minister of SMEs and Startups at the ‘2025 Incheon Startup Activation Merit Awards.’ This award is an event organized by the Incheon Regional Office of SMEs and Startups and jointly promoted by Incheon Metropolitan City to discover and encourage outstanding companies and institutions that have contributed to the activation of the local startup ecosystem.
JNPMEDI has been advancing clinical trial data management and operation systems based on ‘Maven Clinical Cloud,’ which incorporates advanced digital technologies such as AI, cloud, and blockchain. Through this, the company is leading the digital transformation of the domestic pharmaceutical and biotech industry, including the successful execution of confirmatory clinical trials for digital therapeutics through decentralized clinical trials (DCT) for the first time in Korea.
In addition, the company has secured global-level clinical trial quality control and regulatory response capabilities to perform multinational clinical trial projects and strengthened its growth foundation through strategic investment attraction. Recently, it has been establishing its status as an AI-based integrated clinical platform company in the global market by sequentially introducing solutions that support the entire lifecycle of clinical trials, such as database design, document management, and safety management.
CEO Jung Kwon-ho stated, “This award is recognition of JNPMEDI’s achievements in presenting an innovative model for clinical trials and making substantial contributions to the development of the industrial ecosystem. We will continue to provide technologies and services that can respond to the global clinical regulatory environment, contributing to the enhancement of the competitiveness of the domestic pharmaceutical and biotech industry.”
Meanwhile, the ‘2025 Incheon Startup Activation Merit Awards’ was held as an official program of Incheon Startup Week (SURF) 2025, serving as a venue to highlight the achievements and potential of startups that have grown based in Incheon.
| Leading the digital transformation of clinical trials… Achievements in securing global competitiveness recognized
JNPMEDI (CEO Jung Kwon-ho) has received a commendation from the Minister of SMEs and Startups at the ‘2025 Incheon Startup Activation Merit Awards.’ This award is an event organized by the Incheon Regional Office of SMEs and Startups and jointly promoted by Incheon Metropolitan City to discover and encourage outstanding companies and institutions that have contributed to the activation of the local startup ecosystem.
JNPMEDI has been advancing clinical trial data management and operation systems based on ‘Maven Clinical Cloud,’ which incorporates advanced digital technologies such as AI, cloud, and blockchain. Through this, the company is leading the digital transformation of the domestic pharmaceutical and biotech industry, including the successful execution of confirmatory clinical trials for digital therapeutics through decentralized clinical trials (DCT) for the first time in Korea.
In addition, the company has secured global-level clinical trial quality control and regulatory response capabilities to perform multinational clinical trial projects and strengthened its growth foundation through strategic investment attraction. Recently, it has been establishing its status as an AI-based integrated clinical platform company in the global market by sequentially introducing solutions that support the entire lifecycle of clinical trials, such as database design, document management, and safety management.
CEO Jung Kwon-ho stated, “This award is recognition of JNPMEDI’s achievements in presenting an innovative model for clinical trials and making substantial contributions to the development of the industrial ecosystem. We will continue to provide technologies and services that can respond to the global clinical regulatory environment, contributing to the enhancement of the competitiveness of the domestic pharmaceutical and biotech industry.”
Meanwhile, the ‘2025 Incheon Startup Activation Merit Awards’ was held as an official program of Incheon Startup Week (SURF) 2025, serving as a venue to highlight the achievements and potential of startups that have grown based in Incheon.